In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: Therapeutic implication for HIV brain infection

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Gramegna, Pasqua ^a   Latronico, Tiziana ^a   Branà, Maria Teresa ^a   Di Bari, Gaetano ^a   Mengoni, Fabio ^b   Belvisi, Valeria ^c   Mascellino, Maria T ^b   Lichtner, Miriam ^c   Vullo, Vincenzo ^b   Mastroianni, Claudio M ^c   Liuzzi, Grazia M ^a  

^a UNIVERSITY OF BARI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; LIPOPOLYSACCHARIDE; MARAVIROC; PHORBOL 13 ACETATE 12 MYRISTATE; CHEMOKINE RECEPTOR CCR5; CYCLOHEXANE DERIVATIVE; MESSENGER RNA; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; ASTROCYTE; BRAIN INFECTION; CELL ACTIVATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENSITOMETRY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; GLIA CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MICROGLIA; NONHUMAN; PROTEIN EXPRESSION; RAT; SUPERNATANT; ZYMOGRAPHY; ANIMAL; BRAIN; CELL CULTURE; CELL DEATH; CELL SHAPE; CELL SURVIVAL; DRUG ANTAGONISM; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; GLIA; HUMAN; METABOLISM; PATHOLOGY; VIROLOGY;

ANIMALS; ASTROCYTES; BRAIN; CELL DEATH; CELL SHAPE; CELL SURVIVAL; CELLS, CULTURED; CYCLOHEXANES; DOWN-REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HIV INFECTIONS; HUMANS; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEUROGLIA; RATS; RECEPTORS, CCR5; RNA, MESSENGER; TETRADECANOYLPHORBOL ACETATE; TRIAZOLES;

EID: 82955188752     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028499     Document Type: Article

References (39)

1. Hunt PW, (2007) Role of immune activation in HIV pathogenesis. Curr HIV/AIDS Rep 4: 42-47.
2. Soriano V, Geretti AM, Perno CF, Fätkenheuer G, Pillay D, et al. (2008) Optimal use fo maraviroc in clinical practice. AIDS 22: 2231-2240.
3. Lieberman-Blum SS, Fung HB, Bandres JC, (2008) Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther 30: 1228-1250.
4. Gilliam BL, Riedel DJ, Redfield RR, (2010) Clinical use of CCR5 inhibitors in HIV and beyond. J Transl Med 9: 1-14.
5. Valcour V, Sithinamsuwan P, Letendre S, Ances B, (2011) Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep 8: 54-61.
6. Kraft-Terry SD, Stothert AR, Buch S, Gendelman HE, (2010) HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiol Dis 37: 542-528.
7. Toborek M, Lee YW, Flora G, Pu H, András IE, et al. (2005) Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol 25: 181-199.
8. Visse R, Nagase H, (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827-839.
9. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, et al. (2002) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 37: 375-536.
10. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP, (1997) Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74: 111-122.
11. Suryadevara R, Holter S, Borgmann K, Persidsky R, Labenz-Zink C, et al. (2003) Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: links to HIV-1 dementia. Glia 2003 44: 47-56.
12. Mastroianni CM, Liuzzi GM, (2007) Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies. Trends Mol Med 13: 449-459.
13. Liuzzi GM, Mastroianni CM, Latronico T, Mengoni F, Fasano A, et al. (2004) Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia. Brain 127: 398-407.
14. Latronico T, Liuzzi GM, Riccio P, Lichtner M, Mengoni F, et al. (2007) Antiretroviral therapy inhibits matrix metalloproteinase-9 from blood mononuclear cells of HIV-infected patients. AIDS 21: 677-684.
15. Nakajima K, Hamanoue M, Shimojo M, Takei N, Kohsaka S, (1989) Characterization of microglia isolated from a primary culture of embryonic rat brain by a simplieded method. Biomed Res 10: 411-423.
16. Gebicke-Haerter PJ, Bauer J, Schobert A, Northoff H, (1989) Lipopolysaccharide free conditions in primary astrocyte cultures allow growth and isolation of microglial cells. J Neurosci 9: 183-194.
17. McCarthy KD, de Vellis J, (1980) Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85: 890-902.
18. Mosmann T, (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
19. Heussen C, Dowdle EB, (1980) Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 102: 196-202.
20. Shapshak P, Kangueane P, Fujimura RK, Commins D, Chiappelli F, et al. (2011) Editorial neuroAIDS review. AIDS 25: 123-141.
21. Harezlak J, Buchthal S, Taylor M, Schifitto G, Zhong J, et al. (2011) Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS 25: 625-633.
22. Edén A, Fuchs D, Hagberg L, Nilsson S, Spudich S, et al. (2010) HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis 202: 1819-1822.
23. Cardenas VA, Meyerhoff DJ, Studholme C, Kornak J, Rothlind J, et al. (2009) Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. J Neurovirol 15: 324-333.
24. Sorce S, Myburgh R, Krause KH, (2011) The chemokine receptor CCR5 in the central nervous system. Prog Neurobiol 93: 297-311.
25. Agrawal L, Maxwell CR, Peters PJ, Clapham PR, Liu SM, et al. (2009) Complexity in human immunodeficiency virus type 1 (HIV-1) co-receptor usage: roles of CCR3 and CCR5 in HIV-1 infection of monocyte-derived macrophages and brain microglia. J Gen Virol 90: 710-722.
26. Webster NL, Crowe SM, (2006) Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV-related diseases. J Leukoc Biol 80: 1052-1066.
27. Weeks BS, (1998) The role of HIV-1 activated leukocyte adhesion mechanisms and matrix metalloproteinases secretion in AIDS pathogenesis. Int J Mol Med 1: 361-366.
28. Elkington PT, O'Kane CM, Friedland JS, (2005) The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol 142: 12-20.
29. Rizza SA, Badley AD, (2008) HIV protease inhibitors impact on apoptosis. Med Chem 4: 75-79.
30. Hisatomi T, Nakazawa T, Noda K, Almulki L, Miyahara S, et al. (2008) HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice. J Clin Invest 118: 2025-2038.
31. Soriano V, Perno CF, Kaiser R, Calvez V, Gatell JM, et al. (2009) When and how to use maraviroc in HIV-infected patients. AIDS 23: 2377-2385.
32. Corbeau P, Reynes J, (2009) CCR5 antagonism in HIV infection: ways, effects, and side effects. AIDS 23: 1931-1943.
33. Rossi R, Lichtner M, Sauzullo I, Mengoni F, Marocco R, et al. (2010) Downregulation of leukocyte migration after treatment with CCR5 antagonist maraviroc. J Acquir Immune Defic Syndr 54: e13-14.
34. Rossi R, Lichtner M, De Rosa A, Sauzullo I, Mengoni F, et al. (2011) In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. Clin Exp Immunol 166: 184-190.
35. Glass WG, Hickey MJ, Hardison JL, Liu MT, Manning JE, et al. (2004) Antibody targeting of the CC chemokine ligand 5 results in diminished leukocyte infiltration into the central nervous system and reduced neurologic disease in a viral model of multiple sclerosis. J Immunol 172: 4018-4025.
36. Gottschall PE, Yu X, Bing B, (1995a) Increased production of gelatinase B (matrix metalloproteinase-9) and interleukin-6 by activated rat microglia in culture. J Neurosci Res 42: 335-342.
37. Gottschall PE, Yu X, (1995b) Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes. J Neurochem 64: 1513-1520.
38. Lee WJ, Shin CY, Yoo BK, Ryu JR, Choi EY, et al. (2003) Induction of matrix metalloproteinase-9 (MMP-9) in lipopolysaccharide-stimulated primary astrocytes is mediated by extracellular signal-regulated protein kinase 1/2 (Erk1/2). Glia 41: 15-24.
39. Masure S, Billiau A, Van Damme J, Opdenakker G, (1990) Human hepatoma cells produce an 85 kDa gelatinase regulated by phorbol 12-myristate 13-acetate. Biochim Byophys Acta 1054: 317-325.